Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM27ZJG)

Drug Name

AKST4290 Drug Info

Synonyms

Lazucirnon; ALK4290; ALK-4290; AKST4290; 1251528-23-0; Lazucirnon [USAN]; ALK429; AKST-4290; R0T9LLR4TN; BI144807; ALK-429; Lazucirnon (USAN); 2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4-carboxamide; 2-((((2R)-1-(1-((4-Chloro-3-methylphenyl)methyl)-4-piperidinyl)-5-oxo-2-pyrrolidinyl)carbonyl)amino)-N,N,6-trimethyl-4-pyridinecarboxamide; 4-Pyridinecarboxamide, 2-((((2R)-1-(1-((4-chloro-3-methylphenyl)methyl)-4-piperidinyl)-5-oxo-2-pyrrolidinyl)carbonyl)amino)-N,N,6-trimethyl-; LAZUCIRNON [INN]; UNII-R0T9LLR4TN; SCHEMBL1668125; CHEMBL3670800; GTPL10653; BDBM123072; GLXC-26875; WHO 11481; AKOS040755379; DB15269; MS-29506; Example 11 [WO2012045803A1]; HY-136788; CS-0133685; D11741; US8742115, 11; 2-{(2R)-1-[1-(4-Chloro-3-methylbenzyl)piperidin-4-yl]-5-oxopyrrolidin-2-carboxamido}-N,N,6-trimethylpyridine-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 59534386
TTD Drug ID: DM27ZJG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 3 (CCR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD-1744	DMCOMG5	Asthma	CA23	Discontinued in Phase 1	[3]
DPC-168	DMA7DH0	Allergic rhinitis	CA08.0	Discontinued in Phase 1	[4]
YM-344031	DMMUYC2	Asthma	CA23	Preclinical	[5]
YM-355179	DMTM1LK	Asthma	CA23	Preclinical	[5]
QAP-642	DM8RHST	Allergic rhinitis	CA08.0	Terminated	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 3 (CCR3)	TTD3XFU	CCR3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04369430) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment. U.S.National Institutes of Health.
2	SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022 Jun 1;42(6):1038-1046.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7.
5	Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
6	New Drugs and Targets for Asthma and COPD. T.T. Hansel, P.J. Barnes. 2010. Page 158.